As previously stated by Starpharma in announcements over the years, once phase 2 of the three in house trials have been completed and licensed out to a tier 1 pharma, a 505(b)(2) application may be made to the regulatory authorities to bypass phase 3 clinical trials and bring straight to market our Dep Docetaxel, Dep Cabazitaxel, and Dep Irinotecan
We are now approaching the completion of the monotherapy trials.
Based on information out in the market place in regards to licensing deals, a nine figure sum for each of the 3 in house drugs could be forthcoming
On another note..........looks like our new CFO has great credentials
In regards to the current phase 1/2 AZD trials, one wonders which of them will get to phase 2 first
A Phase I/II Study of AZD0466 as Monotherapy or in Combination with Anticancer Agents in Advanced Non-Hodgkin Lymphoma
Study of AZD0466 monotherapy or in combination in patients with advanced haematological malignancies
If I was to guess it would be NCT04865419
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $52.27M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4200 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 108148 | 2 |
View Market Depth
| Last trade - 16.21pm 11/09/2025 (20 minute delay) ? |
| SPL (ASX) Chart |
Day chart unavailable